Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones
Disc Medicine says Phase 2 RESTORE-PV data shows DISC-3405 reduces phlebotomy needs and controls hematocrit in polycythemia vera patients.
Disc Medicine tested a new medicine on patients with a blood condition and showed it helped them need fewer treatments. When a company shows their medicine is working, that is a sign they may be getting closer to selling it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.